LifeMD price to free cash flow LFMD

Market value divided by free cash flow over the last twelve months, since 2023.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 44.5×; Jul 2026
3-year median: 17.8×
3-year range: 10.0× to 309×
Peer median: 17.0×

LifeMD's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Jul 2026, at 44.5×.

On the days it had one over the last 3 years, its median was 17.8×, from 10.0× in Mar 2025 to 309× in Dec 2023.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	44.5×	11.5×	62.2×
2025	15.1×	10.0×	48.1×
2024	11.1×	10.8×	288×
2023	298×	242×	309×

Against its peers

Companies in Healthcare nearest LifeMD's size, closest first, today.

Company	Price to free cash flow
LFMDLifeMD	n/m
KEQUKewaunee Scientific	8.7×
ICCCImmucell	22.1×
LFVNLifevantage	11.0×
SPROSpero Therapeutics	n/m
APTAlpha Pro Tech	9.7×
PDEXPro DEX	29.5×
PLXProtalix BioTherapeutics	26.8×
NATRNatures Sunshine Products	11.8×
ATNMActinium Pharmaceuticals	n/m
ELMDElectromed	26.2×
Peer median	17.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on LifeMD

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.